Corneal Endothelial Cell Density in Eyes Treated With a Fluocinolone Acetonide Intravitreal Implant

NCT03145025 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2019-06-21

No results posted yet for this study

Summary

An Observational Change-From-Baseline Evaluation of Corneal Endothelial Cell Density in Eyes Treated with a Fluocinolone Acetonide Intravitreal Implant

Conditions

  • Uveitis, Posterior

Interventions

DEVICE

Retisert

Intravitreal Implant

DRUG

Fluocinolone Acetonide Intravitreal Implant

Intravitreal Implant

Sponsors & Collaborators

  • Bausch & Lomb Incorporated

    lead INDUSTRY

Eligibility

Min Age
12 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-07-14
Primary Completion
2018-09-10
Completion
2019-03-22
FDA Drug
Yes
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03145025 on ClinicalTrials.gov